Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05260359 · ClinicalTrials.gov registry record · Phase 2
Dermal Irritation, Sensitization and Cumulative Irritation Potential of 6% Bemotrizinol
A Phase 2 study of Sunburn, sponsored by dsm-firmenich Switzerland.
- Completed
- Registry status
- Phase 2
- Development phase
- 224
- Enrollment target
- 1
- Study location
NCT05260359: Completed Phase 2 study of Sunburn, sponsored by dsm-firmenich Switzerland.
NCT05260359 is a Phase 2 study of Sunburn that has completed, run by dsm-firmenich Switzerland. The registered enrollment target is 224 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05260359, a Phase 2 study of Sunburn, has completed, sponsored by dsm-firmenich Switzerland.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 224 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this clinical trial is to evaluate the dermal safety of Bemotrizinol (6%).
Primary Outcome
Dermal irritation and/or sensitization rated based on following scoring system: 0 - No evidence of irritation 1. \- Minimal erythema, barely perceptible 2. \- Definite erythema, readily visible; minimal edema or minimal papular response 3. \- Erythema and papules 4. \- Definite edema 5. \- Erythema, edema, and papules 6. \- Vesicular eruption 7. \- Strong reaction spreading beyond test site
Conditions Studied
Interventions
- OTHER 0.9% Saline
- DRUG 6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation
- DRUG 6% Bemotrizinol (BEMT) dispersion in petrolatum
- OTHER Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT
- OTHER Petrolatum vehicle
Study Locations (1)
New Jersey
- Eurofins | CRL, Inc. - Piscataway
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2022-02-23 |
| Est. Completion | 2022-04-08 |
| Phase | Phase 2 |
What the finished NCT05260359 record still lists
NCT05260359 is an interventional study that assigns participants to a tested intervention. The registered 224 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% higher).
The record links to 1 condition, with Sunburn appearing as the primary indexed condition, and to 5 interventions - of which 0.9% Saline is the first listed.
NCT05260359 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT05260359 about?
NCT05260359 is a clinical study titled "Dermal Irritation, Sensitization and Cumulative Irritation Potential of 6% Bemotrizinol". The purpose of this clinical trial is to evaluate the dermal safety of Bemotrizinol (6%).
What is the current status of trial NCT05260359?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 224 participants. The study started on 2022-02-23. Estimated completion is 2022-04-08.
What conditions does trial NCT05260359 study?
This clinical trial studies the following conditions: Sunburn.
What interventions are being tested in trial NCT05260359?
The interventions under investigation include: 0.9% Saline (OTHER), 6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation (DRUG), 6% Bemotrizinol (BEMT) dispersion in petrolatum (DRUG), Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT (OTHER), Petrolatum vehicle (OTHER).
Who is sponsoring clinical trial NCT05260359?
This trial is sponsored by dsm-firmenich Switzerland, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05260359 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sunburn
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05260359's enrollment target sits among peer trials
224 269th of 2000 higher than 1,727 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02706561 · 224 participants · NA
Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery
- NCT04140344 · 224 participants · NA
The NOTICE Study: Neurosurgery and OrThopedIcs Communication Evaluation Study Following Lumbar Fusions
- NCT04915183 · 224 participants · Phase 2
Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
- NCT05519878 · 224 participants · NA
Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI